Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Debt Repayments (2016 - 2025)

IGC Pharma (IGC) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • Quarterly Long-Term Debt Repayments fell 66.67% to $1000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$3000.0 through Sep 2025, down 400.0% year-over-year, with the annual reading at -$3000.0 for FY2025, 0.0% changed from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $1000.0 at IGC Pharma, roughly flat from $1000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $4000.0 in Q4 2023, with the low at -$5000.0 in Q1 2024.
  • Average Long-Term Debt Repayments over 5 years is -$666.67, with a median of -$1000.0 recorded in 2021.
  • Peak annual rise in Long-Term Debt Repayments hit 400.0% in 2024, while the deepest fall reached 400.0% in 2024.
  • Over 5 years, Long-Term Debt Repayments stood at -$1000.0 in 2021, then changed by 0.0% to -$1000.0 in 2022, then skyrocketed by 500.0% to $4000.0 in 2023, then crashed by 225.0% to -$5000.0 in 2024, then surged by 120.0% to $1000.0 in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $1000.0, $1000.0, and -$5000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.